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Objective: To determine the mortality rate of children, adolescents and adults with sickle
cell anemia in Rio de Janeiro, Brazil.
Methods: The number of deaths, the mortality rate and the causes of deaths in patients with
sickle cell anemia who were treated and followed up at our institution for 15 years were
determined and compared to data available for the Brazilian population.
Results: The overall number of deaths was 281 patients with a mortality rate of 16.77%.
Survival probability was signiﬁcantly higher in females. The number of deaths and the mor-
tality rate were age-speciﬁc with a signiﬁcant increase in the 19- to 29-year-old age group.
The remaining life expectancy of the patients with sickle cell anemia was less than that of
Brazilians at large. The gap between the two was about 20 years for ages between one and
ﬁve years with this gap decreasing to ten years after the age of 65 years. The most com-
mon causes of death were infection, acute chest syndrome, overt stroke, organ damage and
sudden death during painful crises.
Conclusion: To the best of our knowledge, this is the ﬁrst Brazilian study in a single institution
in Rio de Janeiro; themortality ratewas 18.87% among adult patientswith sickle cell anemia.
The mortality rates in children and adults are higher than those reported in developed
countries of the northern hemisphere.
© 2017 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The mortality rate among infants, children and young adults
with sickle cell disease (SCD) in general and sickle cell ane-
mia (SCA) in particular is high. The overall death rates in
under 20-year-old children reported by the Cooperative Study
of Sickle Cell Disease (CSSCD) about 30 years ago were 2.6%
for patients with all types of SCD and 3.3% for patients with
SCA.1 Sickle cell disease-related mortality decreased signiﬁ-
cantly from 1999 to 2009 in the USA in all pediatric age groups
up to age 19 years.2 This decline in mortality was the highest
for children younger than one year where the decrease was
61% less than the mortality rate during 1979–1998.2 The mor-
tality in young adults (ages 20–24 years), however, increased
sharply compared to themortality in children ages 15–19 years
from 0.6/100,000 to 1.4/100,000.2 This increase is attributed
to problems associated with the transition from pediatric to
adult care.
Unlike the USA, the mortality rate in developing countries
continues to be high especially in Africa.3,4 In the state of
Minas Gerais, Brazil the mortality rate among children with
SCD born during 2009–2011 was not signiﬁcantly different
from that for children born during 1999–2001 (6.2% vs. 5.8%).5
This suggests that newborn screening alone is not enough to
reduce the mortality rate of children with SCA. Regular follow-
ups, compliance to treatment, family support and the style of
life are important factors to maintain the decreases in both
morbidity and mortality rates. The purpose of this study was
to determine the mortality rates and the cause of death in
children, adolescents and adults with SCA followed-up at a
single institution in Rio de Janeiro and compare these rates to
Brazilian children and adults at large.
Methods
Patients
Data of patients with SCA including patients with sickle/0-
thalassemia (S/0thal), who were seen and followed at
HEMORIO for 15 years from January 1, 1998 through December
31, 2012 were retrospectively collected and analyzed. Children
(<18 years old) and adults (≥18 years) were included in the
study. Age and sex relatedmortalitywere also determined and
compared to available data of the Brazilian population at large.
The diagnosis of SCA including S/0thal was conﬁrmed by
high performance liquid chromatography (HPLC) as previously
described.6 The date and cause of deaths were conﬁrmed on
patients’ charts if death occurred at HEMORIO. Death outside
HEMORIO, suspected when patients failed to show up for a
follow-up,was conﬁrmedby interviewswith thepatient’s fam-
ilies and from death certiﬁcates. Accordingly, the death of 69
patients occurred outside HEMORIO. The family brought the
death certiﬁcates of 62 patients. Of these 13 deaths were due
to accidents unrelated to SCA and in 49 patients, death was
due to stroke, acute chest syndrome (ACS) or infection. The
cause of death in the remaining seven patients was not clear
or could not be conﬁrmed and hence, their cause of death was
included in the unknown category.
The study was approved by the Institutional Review Board
of HEMORIO.
Statistical analysis
Statistical analysis was performed using the R software7 and
the Kaplan–Meier estimator to assess the overall survival of
patients with SCA. Comparison of survival curves was made
using the Tarone-Ware test.8 Exclusions from statistical anal-
yses included patients whose deaths were unrelated to SCD
and those whose cause of death was unknown. Compar-
isons of frequencies between nominal variables were made
using the chi-squared test without continuity correction or
the Fisher exact test. Determination of the average remaining
life expectancy was determined by the empirical likelihood
(Emplik) ratio test package9 of the R software. Statistical sig-
niﬁcance was based on a p-value <0.05.
Results
The total number of patients enrolled in this study was 1676.
Age (both at enrollment and at death) and sex are summarized
in Table 1. A total of 281 patients died during the study period
(Table 1). The mortality rate is summarized in Table 2.
A Kaplan Meier analysis8 of the survival probability of all
enrolled patients showed that survival of females was signiﬁ-
cantly higher than males (p-value=0.007). The median age of
survival was 53.3 years for males and 56.5 years for females
(Figure 1). The median age at death was 28.98 years for men
and 34.02 years for women (Table 1).
Table 1 – Characteristics of patients with sickle cell
anemia.
Female Male Total
Patients – n
(%)
889 (53) 787 (47) 1676 (100)
Deaths – n (%) 139 (49) 142 (51) 281 (100)
Age at
enrollment
(years) –
mean±SD
12.52±11.06 10.99±10.46 11.80±10.81
Median
(range)
8.89 (0.02–66.99) 7.30 (0.14–62.66) 8.12 (0.02–66.99)
Age at death
(years) –
mean±SD
33.85±14.80 32.71±14.25 33.27±14.51
Median
(range)
34.02 (2.74–74.79) 28.98 (0.56–68.03) 31.98 (0.56–74.79)
SD: standard deviation.
Table 2 – Mortality rate of the enrolled patients.
Patients Deaths Mortality rate
n n %
Children (<18 years old) 420 44 10.48
Adults (>18 years old) 1256 237 18.87
All patients 1676 281 16.77
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Figure 1 – Kaplan–Meier curves of patients with sickle cell
anemia stratiﬁed by sex. The median age of survival of
males is 53.3 years, while for females the median survival
is 56.5 years. The Tarone-Ware test indicates a statistically
signiﬁcant difference between the curves (p-value=0.007).
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Figure 2 – The mortality rate varies considerably between
the age groups. The mortality rate decreases signiﬁcantly
after the age of ﬁve years and increases signiﬁcantly after
the age of 18 years.
Themortality among patients varied signiﬁcantlywith age.
As shown in Figure 2 the mortality rate in under 5-year-old
patients was lower than the mortality rate in the 6–11 age
group. However, there was a signiﬁcant difference in the mor-
tality rates between the 6–11 and 12–18 age groups. After the
age of 18 years, there was a signiﬁcant and sudden increase in
the mortality in the 19–29 age group. The mortality continued
to increase signiﬁcantly after the age of 30 years.
The following assumptions were made in order to compare
the life expectancy of patients with SCA in Rio de Janeiro with
the life expectancy of Brazilians at large. The prevalence of
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Figure 3 – The average remaining life expectancy for
Brazilians and for the patients with sickle cell anemia
enrolled in this study.
SCD in the state of Rio de Janeiro is the second highest in Brazil
after the state of Minas Gerais. In 2016, about 4000 patients
with SCD were treated at HEMORIO representing about 80% of
the patients with SCD in the state of Rio de Janeiro. Thus, by
extrapolation we assumed that the life expectancy of patients
with SCA in Rio de Janeiro may represent the life expectancy
of patients with SCA in Brazil. We next compared the life
expectancy of patients with SCA described in this study with
the life expectancy in Brazilians at large (Figure 3). The latter
was based on the 2013 life expectancy report of Brazilians pub-
lished by the Instituto Brasileiro de Geograﬁa e Estatistica (IBGE).10
It is important to note that life tables are used to measure the
mortality, survival, and remaining lifetime of a population at
various ages as previously described.11,12
Accordingly, the life expectancy of Brazilian males is 71.0
years and for females it is 78.3 years and the estimated life
expectancy for both sexes at birth is 74.6 years (Table 3). The
remaining life expectancy at birth of the patients with SCA
is 53.3 years, that is, 21.3 years less than the life expectancy
of Brazilians at large. Between the ages of one and ﬁve years,
the remaining life expectancy of the patients in this study is
about 22 years less than that of Brazilians at large. This gap
decreased to about ten years after the age of 60 as shown in
Table 3.
The causes of death of the 281 patients who died are listed
in Table 4. The most common causes of death were infection,
mostly due to sepsis, ACS, overt stroke, sudden death during
painful crises and organ damage due to hepatic or renal fail-
ure. Thirteen patients died of unrelated causes mostly due to
trauma.
Discussion
Although previous studies determined the mortality rate in
Brazilian children with SCA, to the best of our knowledge this
is the ﬁrst study that determined the mortality rate in Rio de
Janeiro and probably, by extrapolation, in Brazilian adults with
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Table 3 – Average remaining life expectancy of sickle cell anemia (SCA) patients compared to that of Brazilians at large.
Age Life expectancy Brazilians Life expectancy SCA patients Age Life expectancy Brazilians Life expectancy SCA patients
0 74.6 53.3 38 40.1 21.4
1 74.8 52.3 39 39.2 20.9
2 73.8 51.3 40 38.3 20.0
3 72.9 50.4 41 37.4 19.4
4 71.9 49.4 42 36.5 19.0
5 71.0 48.4 43 35.6 18.5
6 70.0 47.4 44 34.7 17.8
7 69.0 46.5 45 33.9 17.3
8 68.0 45.6 46 33.0 16.7
9 67.0 44.6 47 32.1 16.3
10 66.0 43.7 48 31.3 15.8
11 65.1 42.7 49 30.4 15.1
12 64.1 41.8 50 29.6 14.1
13 63.1 40.9 51 28.8 13.5
14 62.1 39.9 52 27.9 12.9
15 61.2 39.0 53 27.1 12.5
16 60.2 38.1 54 26.3 12.7
17 59.3 37.3 55 25.5 12.4
18 58.3 36.4 56 24.7 11.4
19 57.4 35.5 57 23.9 10.9
20 56.5 34.7 58 23.2 10.8
21 55.6 33.9 59 22.4 10.3
22 54.7 33.2 60 21.6 10.8
23 53.8 32.4 61 20.9 10.8
24 52.8 31.8 62 20.1 9.8
25 51.9 31.0 63 19.4 9.4
26 51.0 30.3 64 18.7 8.4
27 50.1 29.4 65 18.0 7.4
28 49.2 28.7 66 17.3 6.4
29 48.3 28.1 67 16.6 5.4
30 47.4 27.4 68 15.9 4.4
31 46.5 26.7 69 15.2 4.1
32 45.5 25.8 70 14.6 3.1
33 44.6 25.0 71 14.0 2.1
34 43.7 24.3 72 13.4 2.8
35 42.8 23.7 73 12.8 1.8
36 41.9 22.8 74 12.2 0.8
37 41.0 22.1
Table 4 – Causes of death of the patients with sickle cell
anemia.
Cause n %
Acute chest syndrome 71 25.27
Cardiac causes 13 4.63
Hemolytic crisis 4 1.42
Hepatic crisis 1 0.36
Infection 82 29.18
Organ damage 30 10.68
Overt stroke 33 11.74
Splenic sequestration 1 0.36
Sudden during painful crisis 26 9.25
Unknown 7 2.49
Unrelated 13 4.63
Total 281 100
SCA. The overall 10.48% mortality rate of all children in this
study is higher than that reported in the USA and Europe1,2,13
but similar to other reports on Brazilian children.5,14 More-
over, the Minas Gerais study reported no signiﬁcant difference
in the mortality rate in 1999–2001 after the initiation of their
newborn screening program in 1998 compared to that in
2009–2011.5
On comparing age groups, after the signiﬁcant decrease in
the mortality rate in children aged 6–11 years and in adoles-
cents, there was a sudden and sharp increase in the mortality
rate in patients aged 19–29 years similar to that reported in
the USA. This surge in mortality after adolescence is not well
understood and usually it is assumed to be due to a num-
ber of issues related to the psychosocial domain.2,15 However,
this sudden increase in mortality in patients with SCD aged
>18 years of age was not present in a Belgian study that eval-
uated the survival of patients with SCD recorded in the SCD
registry.13
As reported in previous studies, the mortality rate in
children is similar between males and females.1,2,16,17 The
divergence in the mortality rate between the sexes in favor
of females becomes apparent in adults as shown in this
report as well as in previous studies.1,18 The reason why
adult women with SCA live longer than males is not known.
One possibility is that Hb F may be higher in females due
to the partial control of Hb F by an X-linked gene located
at Xp22.2.19–21 Another possibility is the relatively lower
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blood viscosity due to lower Hb and hematocrit levels in
women.
In order to determine the signiﬁcance of the mortality rate
of patients with SCA, the data of this study were compared
with what is known about mortality in children and the life
expectancy in the Brazilian population. The last mortality rate
for all children <5 years of age in Brazil reported by the United
Nations Children’s Fund (UNICEF)22 was 1.6% for males and
1.3% for females. These rates are 14.3% for males and 33.3%
for females with SCA in the current study. Thus, the mor-
tality rates for under 5-year-old patients with SCA in Rio de
Janeiro are about 8.9 times and 25.6 times higher for males
and females, respectively. Moreover, the mean difference in
average remaining life expectancy for a Brazilian patient with
SCA in Rio de Janeiro is 17.6 years (range: 10.0–22.6 years) less
than that in the general Brazilian population.7,9,10 The average
life expectancy for Brazilians at birth is 74.6 years. The mean
survival of Brazilian patients with SCA is 53.3 years, 21.3 years
less than the general population.
Among the known causes of death due to SCA, infection
was the most common cause of death in both children and
adults followed by ACS. The most common causes of death in
the Brazilian population at large are heart problems, stroke,
pneumonia, chronic obstructive pulmonary disease and dia-
betes mellitus.23
In conclusion, to the best of our knowledge this is the
ﬁrst Brazilian study that reports the mortality rate among
adult patients with SCA in Rio de Janeiro. Unfortunately, this
mortality rate is higher than that reported in developed coun-
tries in the northern hemisphere. Similarly, the mortality rate
amongBrazilian childrenwithSCA ishigher than that indevel-
oped countries. We hope that the mortality rate in Brazilian
children and adults will decrease with time as the experi-
ence of providers and logistic issues of the newborn screening
program improve. Currently, newborn screening seems to be
necessary but not sufﬁcient to reduce the mortality rate of
children with SCA. In addition, other factors such as regular
follow-ups, compliance to treatment, family support and the
style of life are important factors to decrease both morbidity
and mortality.
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